– USA, CA – Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, today announced the appointment of Dr. Rajiv Patni (M.D.) to its Board of Directors, bringing to the Board nearly 25 years of global product development experience in a diverse set of therapeutic areas, including cardiology, diabetology, hepatology, neurology, and benign hematology.
“We are pleased to welcome a proven clinical development leader of Dr. Rajiv Patni’s caliber to our Board of Directors. With expertise that spans the continuum from translational to registrational studies and regulatory agency negotiation in several rare diseases, we look forward to his valuable contribution and perspective as the Board supports Quince’s next phase of growth,” said Board Chair, David Lamond.
About Dr. Rajiv Patni
Most recently, Dr. Rajiv Patni served as CRDO at Reata Pharmaceuticals, a commercial-stage company recently acquired by Biogen. Previously, Dr. Patni also served as CMO at several successful public, small-cap, and commercial-stage biopharmaceutical companies – Global Blood Therapeutics, Portola Pharmaceuticals, and Adamas Pharmaceuticals. He joined these companies at an inflection point in their R&D growth trajectories and contributed to their acquisition by larger companies. Earlier in his career, Dr. Patni held roles of increasing responsibility at Pfizer, Roche, and Actelion. His proven track record in fostering successful team efforts at these companies contributed to the approval of 11 medicines from the U.S. Food and Drug Administration, the European Medicines Agency, and other regulatory agencies. Recent approvals include medicines for several rare diseases, including pulmonary arterial hypertension, advanced Parkinson’s disease, sickle cell disease, and Friedrich’s ataxia. He received his M.D. from the Icahn School of Medicine at Mount Sinai in New York City as part of an accelerated B.S./M.D. program. He completed an internal medicine residency and adult cardiology fellowship at the Albert Einstein College of Medicine, also in New York City, where he continued as an attending physician-scientist before joining the biopharmaceutical industry.
About Quince Therapeutics
Quince Therapeutics is a late-stage biotechnology company dedicated to unlocking the potential of a patient’s biology to deliver innovative and life-changing therapeutics to those living with rare diseases.
SOURCE: https://quincetx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
